Those Covid-19 variants? ‘Don’t worry yet,’ vaccine expert says
Paul Offit, the vaccine developer, explains why there’s enough evidence to make it an issue worth watching, nonetheless.
Paul Offit, the vaccine developer, explains why there’s enough evidence to make it an issue worth watching, nonetheless.
Wastewater surveillance, which demonstrated great potential during the Covid-19 pandemic, remains vastly under-leveraged for H5N1 bird flu at this precarious moment.
As national awareness of mental illness rises and innovative care models emerge, many advocates now see a rare opportunity to remake mental health crisis care…
Three years ago, Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it’s backing out.
CVS Health missed its Q1 projections and lowered its full-year outlook, citing medical cost hikes with Medicare Advantage patients. Its stock price slid.
On Wednesday, UnitedHealth CEO Andrew Witty appeared before Congress to answer for what lawmakers called a “single attack kicked off a cascading series of
As part of its reporting on Mount Sinai and the Living Brain Project, STAT sent a list of written questions to Mount Sinai. Here are…
An experimental gene therapy seems to alleviate skeletal defects tied to rare inherited disease, a new study shows.
Extensive testing of pasteurized commercially purchased milk and other dairy products from 38 states found no evidence of live H5N1 bird flu virus.
The movement to embrace state execution by means of nitrogen has a troubling new development.
On a new “First Opinion Podcast” episode, physician Joel Zivot, an advocate against the use of medicine in capital punishment, speaks about what it means…